No abstract

The worldwide variation in asthma prevalence prompted us to carry out a study to assess the variability of asthma-related symptoms in young adults on the islands of Gran Canaria and Tenerife. We used the questionnaire used in the European Community Respiratory Health Survey with the addition of two questions on smoking and ancestors from the Canary Islands. In each island, this questionnaire was distributed to a random sample of 5000 subjects aged 20-44 years. Of the 10,000 subjects, 9,506 (95.06%) were considered eligible. We obtained 7,132 (75.03%) responses. The prevalence of the different symptoms was wheezing 25.3%, nocturnal thoracic tightness 18.0%, awakened by an attack of shortness of breath 13.1%, attack of nocturnal coughing 33.3%, attack of asthma 4.3%, current asthma treatment 6.2%, and nasal allergies 18.0%. Women and smokers showed a significantly higher prevalence of asthma symptoms. No significant difference in symptoms was found between subjects whose ancestors were of Canarian origin and those with ancestors born outside the Canaries. As has been observed on other islands (Great Britain and New Zealand), asthma is common in individuals from 20 to 44 years of age in the Canaries. We hypothesize that climatic conditions play an important role in the prevalence of asthma symptoms.

Inhaled nitric oxide (iNO) has been shown to be a potent and selective vasodilator in pulmonary arterial hypertension (PAH). However, the clinical experience in prolonged treatment is limited. We assess the safety and effectiveness of long-term administration of iNO in severe PAH. Two female patients were admitted to our hospital because of severe dyspnea (World Health Organization functional class IV) and hypoxemia. They were diagnosed with PAH (primary and secondary to congenital heart disease) and treated with iNO for 2 years. The delivery system consisted of an NO tank of 800 ppm, a modified gas-pulsing device, and nasal cannulas. On iNO treatment the patients showed remarkable improvement of symptoms, oxygenation and 6-min walk distance. After 16 months the patients began to experience a progressive rebound of symptoms. A phosphodiesterase type 5 inhibitor (dipyridamole) was added to iNO. This intervention proved useful in improving clinical deterioration and hemodynamics. This is the first study reporting 2-year iNO therapy in 2 patients with primary and secondary pulmonary hypertension. The combination of dipyridamole with iNO augments the pulmonary vasodilatation and may be useful in managing PAH.

No abstract

Simplified and conventional thoracic sympathectomy resulted in a long-term reduction in FEV(1), FEF(25%-75%), DLCO, and resting and maximal heart rate, as well as a mild but significant increase in airway resistance in the conventional thoracic sympathectomy group, without any clinical consequence to the patient. These changes were unrelated to the level of transection of the thoracic sympathetic chain.